Related Experiment Videos
Early Manifest Glaucoma Trial: design and baseline data
1Department of Preventive Medicine, University Medical Center at Stony Brook, New York 11794-8036, USA. cleske@uhmc.sunysb.edu
Ophthalmology
|November 26, 1999
Summary
The Early Manifest Glaucoma Trial (EMGT) investigates reducing intraocular pressure (IOP) in early open-angle glaucoma. This study will inform glaucoma management and screening by examining IOP reduction
Area of Science:
- Ophthalmology
- Clinical Trials
- Glaucoma Research
Background:
- Early open-angle glaucoma requires effective treatment strategies.
- Understanding the natural history of glaucoma is crucial for patient management.
- The role of intraocular pressure (IOP) reduction in early disease is not fully established.
Purpose of the Study:
- To evaluate the effectiveness of reducing intraocular pressure (IOP) in early, previously untreated open-angle glaucoma.
- To explore factors influencing glaucoma progression.
- To study the natural history of early open-angle glaucoma.
Main Methods:
- A randomized clinical trial involving 255 newly diagnosed patients aged 50-80.
- Patients were randomized to immediate IOP reduction (laser trabeculoplasty and medication) or no initial treatment.
- Follow-up included regular computerized perimetry, tonometry, and fundus photography to assess progression.
Main Results:
- Baseline data from 255 randomized patients (1993-1997) are presented.
- Mean age was 68.1 years, with 66% women.
- Mean baseline intraocular pressure (IOP) was 20.6 mmHg, with 80% of eyes below 25 mmHg.
Conclusions:
- The Early Manifest Glaucoma Trial (EMGT) is the first large randomized trial to assess immediate IOP reduction in early glaucoma.
- Results will impact clinical management, understanding of IOP's role, and glaucoma screening rationale.
- The study provides critical data on the natural history and progression of early open-angle glaucoma.